Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product (Instruments and Reagents & Kits), By Test Type (Immunodiagnostic Test and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 141.3 Million in 2023 and is expected to exhibit a CAGR of 10.8% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focused on adopting growth strategies such as the launch of new products, and this is expected to drive the global methicillin resistant staphylococcus aureus (MRSA) testing systems market growth. For instance, in January 2020, Vela Diagnostics, a supplier of integrated molecular solutions for the diagnosis of infectious diseases and cancer and innovative test in Singapore, announced the CE-IVD launch of Sentosa SA Direct MRSA/SA PCR test, which provides real-time Polymerase Chain Reaction (PCR) qualitative detection of Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA), to aid in the prevention and control of MRSA/SA infections in healthcare settings.
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.
COVID-19 had a positive impact on the global methicillin resistant staphylococcus aureus (MRSA) testing systems market. For instance, in April 2020, Siemens Healthcare GmbH, is medical device company headquartered in Erlangen, Germany, formally unveiled the RAPIDPoint 500e staphylococcus aureus blood tests for infection, adding to the company's product lineup and supporting COVID-19 initiatives.
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market: Key Developments
On March 15, 2023, Cepheid, a molecular diagnostics company, announced the launch of its first manufacturing unit in India at Mahadeva Kodigehalli, Bengaluru. The 77,000 square-foot facility will manufacture the company’s industry Xpert Staphylococcus Aureus testing cartridges for India and other countries.
On May 30, 2023, Cepheid, a molecular diagnostics company, secured the CE mark for its molecular in vitro diagnostic test, Xpert NPM1 Mutation. The Xpert NPM1 Mutation test quantifies the mRNA transcripts of the A, B, and D mutations accounting for approximately 90% of NPM1 mutant cases, plus the control gene, and provides an easy and convenient method of assessing response to therapy and improving the management of patients with MRSA.
In April 2021, DiaSorin S.p.A., a multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics in Italy, announced that its Board of Directors had approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation is a biotechnology company which develops, manufactures and markets proprietary biological testing technologies with applications in life-sciences in U.S.
In November 2022, Sense Biodetection is Laboratory in Abingdon, England announced that it had entered into a strategic agreement with R-Biopharm Nederland B.V. is Laboratory in Arnhem, Netherlands, for the non-exclusive distribution in the Netherlands, Belgium, and Luxembourg of Sense’s Veros instrument-free, point-of-care molecular testing platform. Veros is the first and only self-contained, single-use MRSA test diagnostic that produces accurate molecular results in approximately 15 minutes, unconstrained by a reader or need for external power.
Browse 38 Market Data Tables and 34 Figures spread through 180 Pages and in-depth TOC on “Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market”- Forecast to 2030, By Product (Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institute), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market :
- The global methicillin resistant staphylococcus aureus (MRSA) testing systems market is expected to exhibit a CAGR of 10.8% during the forecast period. Merger with emerging economies offers lucrative growth opportunities for players in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market. The usage of methicillin resistant staphylococcus aureus (mrsa) testing systems has been driven by high public awareness in developed economies, such as the U.S.
- Among Test Type, the immunodiagnostic segment is expected to hold a dominant position in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market during the forecast period. For instance, in November 2021, Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies in North America, announced a partnership with RxParadigm, a pharmacy benefit manager company delivering transparency and restoring competitiveness to healthcare systems, to offer RxParadigm customers access to immunodiagnostic tests.
- Among region, North America is expected to be the dominant region in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market, as the key players are focusing on spreading awareness of staphylococcus aureus infection. For instance, on May 9, 2023, Small Vulnerable Newborn Series was launched during the International Maternal Newborn Health Conference in Cape Town, South Africa. The event unpacked the five-article Lancet Series which explores the global importance and possibilities of preventing the birth of Small Vulnerable Newborns.
- Major players operating in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market include F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.
